Xenalipin

Xenalipin

SCHEMBL133087

O=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.58
KIF11 P52732 1/20 0.53
GAA P10253 1/20 0.52
BACE1 P56817 1/20 0.51
TACR1 P25103 2/20 0.50
FPR2 P25090 2/20 0.49
HNF4A P41235 1/20 0.49
KLRK1 P26718 2/20 0.47
MICA Q29983 2/20 0.47
RAET1L Q5VY80 2/20 0.47
BCAT2 O15382 1/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
ACLY P53396 1/20 0.47
TRPA1 O75762 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
LTB4R2 Q9NPC1 1/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Xenalipin SCHEMBL29881739 1.00 CYP2C8 (0.58) CYP2C8KIF11GAABACE1TACR1
Xenalipin SCHEMBL3723586 0.98 CYP2C8 (0.56) CYP2C8KIF11GAABACE1TACR1
Xenalipin SCHEMBL27618270 0.91 CYP2C8 (0.65) CYP2C8KIF11GAABACE1TACR1
SCHEMBL29979035 0.86 TACR1 (0.48) CYP2C8TACR1HNF4ABCAT2LTB4R2
SCHEMBL23353984 0.86 TACR1 (0.48) CYP2C8TACR1HNF4ABCAT2LTB4R2
SCHEMBL18759613 0.84 HNF4A (0.63) HNF4ABCAT2LTB4R2
SCHEMBL30292805 0.84 HNF4A (0.63) HNF4ABCAT2LTB4R2
SCHEMBL403609 0.84 GAA (0.51) CYP2C8KIF11GAABACE1TACR1
SCHEMBL2564888 0.84 BCAT2 (0.65) CYP2C8KIF11GAABACE1TACR1
SCHEMBL171542 0.84 TRPV1 (0.54) CYP2C8KIF11GAABACE1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 795 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-10934251-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION (IN) 2021-03-02 US claimed
US-20200190018-A1 Process For The Preparation of Lomitapide HETERO RESEARCH FOUNDATION (IN) 2020-06-18 US claimed
US-20180291773-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2018-10-11 US claimed
US-20180282257-A1 Aromatic Monoester Compositions and Processes for Preparing Same EXXONMOBIL CHEMICAL PATENTS INC. 2018-10-04 US claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20180105487-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2018-04-19 US claimed
EP-3215490-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE Hetero Research Foundation (IN) 2017-09-13 EP claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
WO-1998023593-A1 APO B-SECRETION/MTP INHIBITORY AMIDES PFIZER INC. (US) 1998-06-04 WO claimed
EP-0832069-A1 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION PFIZER INC. (US) 1998-04-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1996040640-A1 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION PFIZER INC. (US) 1996-12-19 WO claimed
EP-0106140-B1 BENZOIC ACID DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1988-08-17 EP claimed
EP-0059983-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT THE WELLCOME FOUNDATION LIMITED (GB) 1986-06-11 EP claimed
EP-0106140-A2 Benzoic acid derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1984-04-25 EP claimed
EP-0059983-A1 Substituted biphenyl compounds for use as a medicament THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS CYP2C8 2897/4885KIF11 2590/4885GAA 360/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS CYP2C8 2897/4885KIF11 2590/4885GAA 360/4885
US-20180105487-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE LIPA, LPAR4, CETP CYP2C8 1045/4885KIF11 420/4885GAA 611/4885
US-20200190018-A1 Process For The Preparation of Lomitapide LIPA, LPAR4, CETP CYP2C8 1045/4885KIF11 420/4885GAA 611/4885
US-10934251-B2 Process for the preparation of lomitapide LIPA, LPAR4, CETP CYP2C8 1045/4885KIF11 420/4885GAA 611/4885
US-20180282257-A1 Aromatic Monoester Compositions and Processes for Preparing Same ADH1A, ADH1C, GK CYP2C8 127/4885KIF11 1500/4885GAA 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.